- NOK3.27bn
- NOK3.17bn
- NOK526.36m
- 95
- 16
- 73
- 68
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 27.6 | ||
| PEG Ratio (f) | 6.11 | ||
| EPS Growth (f) | 4.73% | ||
| Dividend Yield (f) | 2.05% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 8.53 | ||
| Price to Tang. Book | 9.83 | ||
| Price to Free Cashflow | 29.19 | ||
| Price to Sales | 6.07 | ||
| EV to EBITDA | 20.57 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 32.67% | ||
| Return on Equity | 28.31% | ||
| Operating Margin | 23.98% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | NOKm | 363.72 | 363.13 | 427.28 | 491.94 | 526.36 | 551 | 567 | 10.06% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +23.16 | -1.57 | +30.92 | +25.19 | -9 | +11.55 | +2.84 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Medistim ASA is a Norway-based company engaged in the provision of medical equipment and technology. It develops, manufactures and distributes medical devices that measure blood flow and visualize atherosclerosis, and thereby help improve the outcome of cardiac and vascular surgery. The Company provides Transit Time Flow Measurement (TTFM) and ultrasound imaging to the global market to enable medical professionals to reduce risk and enhance quality of cardiac, vascular and transplant surgery. Medistim’s activities are divided into two business units: Own Products Category and Third-Party Products Category. Furthermore, the Company has several subsidiaries, including Medistim USA Inc, Medistim Norge AS and Medistim Japan KK.
Directors
- Oyvin Broymer CHM (71)
- Kari Krogstad PRE (52)
- Bjorn Wiggen VCH (57)
- Thomas Jakobsen CFO
- Mike Farbelow CEX
- Ole Robsrud CEX
- Roger Morberg VPR
- Haege Krogh Wetterhus VPR
- Anders Lillebo VPR
- Tone Veiteberg VPR
- Erik Swensen VRD
- Siri Furst DRC (58)
- Tove Raanes DRC (44)
- Lars Ronn DRC (52)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- February 19th, 1995
- Public Since
- May 28th, 2004
- No. of Shareholders
- 1,028
- No. of Employees
- 152
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Oslo Stock Exchange- Shares in Issue
- 18,314,219
- Address
- Okernveien 94, OSLO, 0579
- Web
- https://medistim.com/
- Phone
- +47 23059660
- Auditors
- BDO AS
Upcoming Events for MEDI
Q4 2024 Medistim ASA Earnings Release
Similar to MEDI
Codelab Capital AS
Oslo Stock Exchange
ContextVision AB
Oslo Stock Exchange
Gentian Diagnostics ASA
Oslo Stock Exchange
INIFY Laboratories AB
Oslo Stock Exchange
Nordhealth AS
Oslo Stock Exchange
FAQ
What is the Medistim ASA share price?
As of Today at 21:58 UTC, shares in Medistim ASA are trading at NOK178.50. This share price information is delayed by 15 minutes.
How has the Medistim ASA share price performed this year?
Shares in Medistim ASA last closed at NOK178.50 and the price had moved by -18.48% over the past 365 days. In terms of relative price strength the Medistim ASA share price has underperformed the FTSE Global All Cap Index by -29.67% over the past year.
What are the analyst and broker recommendations for Medistim ASA?
The overall consensus recommendation for Medistim ASA is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Medistim ASA dividend yield?
The Medistim ASA dividend yield is 2.52% based on the trailing twelve month period.
Does Medistim ASA pay a dividend?
Last year, Medistim ASA paid a total dividend of NOK4.50, and it currently has a trailing dividend yield of 2.52%. We do not have any data on when Medistim ASA is to next pay dividends.
When does Medistim ASA next pay dividends?
We do not have data on when Medistim ASA is to next pay dividends. The historic dividend yield on Medistim ASA shares is currently 2.52%.
How do I buy Medistim ASA shares?
To buy shares in Medistim ASA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Medistim ASA?
As of the previous close price of NOK178.50, shares in Medistim ASA had a market capitalisation of NOK3.27bn.
Where are Medistim ASA shares listed?
Here are the trading details for Medistim ASA:
- Country of listing: Norway
- Exchange: OSL
- Ticker Symbol: MEDI
What kind of share is Medistim ASA?
Based on an overall assessment of its quality, value and momentum Medistim ASA is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Medistim ASA share price forecast for 2024?
The analyst consensus target price for shares in Medistim ASA is NOK190.00. That is 6.44% above the last closing price of NOK178.50.
Analysts covering Medistim ASA currently have a consensus Earnings Per Share (EPS) forecast of NOK6.33 for the next financial year.
Find out moreWhat is the trend in the Medistim ASA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Medistim ASA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -14.83%.
As of the last closing price of NOK178.50, shares in Medistim ASA were trading -4.63% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Medistim ASA PE Ratio?
The Medistim ASA PE ratio based on its reported earnings over the past 12 months is 27.6. The shares last closed at NOK178.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Medistim ASA?
Medistim ASA's management team is headed by:
- Oyvin Broymer - CHM
- Kari Krogstad - PRE
- Bjorn Wiggen - VCH
- Thomas Jakobsen - CFO
- Mike Farbelow - CEX
- Ole Robsrud - CEX
- Roger Morberg - VPR
- Haege Krogh Wetterhus - VPR
- Anders Lillebo - VPR
- Tone Veiteberg - VPR
- Erik Swensen - VRD
- Siri Furst - DRC
- Tove Raanes - DRC
- Lars Ronn - DRC